Chinese oncology drugmaker known for its domestically developed EGFR lung-cancer targeted therapy.
Chinese oncology drugmaker known for its domestically developed EGFR lung-cancer targeted therapy.
Sells furmonertinib in China, where inclusion on the national insurance reimbursement list lifted prescriptions in exchange for lower prices. Outside Greater China, US-based ArriVent BioPharma holds the rights and is running overseas trials, so Allist is paid through milestones and royalties abroad rather than product sales.
In one line: A China-focused AstraZeneca oncology unit, single-drug scale.
Moat: narrow (IP / patents). Patented, domestically developed EGFR inhibitor competing with imported drugs on the reimbursement list.
Headquarters: Shanghai, China · Founded: 2000 · Employees: 1,989
Size Shanghai Allist Pharmaceuticals (688578.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $5.32B, the 439th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥78.99 on 18 Nov 2026.
Performance Over six months the shares fell 14.4%, against +10.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 38.5% over the last twelve months (peer median +13.2%); the operating margin is 46.6% (peer median 19.4%).
Valuation It trades at 12.4× forward earnings against a peer median of 26.6× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +520%, so the hurdle is -520 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 36.7 points above its cost of capital (8.5% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.59B | CN¥5.12B | CN¥3.52B | CN¥1.99B | CN¥789M |
| Revenue growth | — | +46% | +77% | +152% | — |
| Gross profit | CN¥6.29B | CN¥4.92B | CN¥3.34B | CN¥1.88B | CN¥734M |
| EBITDA | n/a | CN¥2.34B | CN¥1.51B | CN¥590M | CN¥64.9M |
| Net income | CN¥2.91B | CN¥2.19B | CN¥1.43B | CN¥644M | CN¥131M |
| Free cash flow | CN¥3.00B | CN¥2.23B | CN¥1.37B | CN¥620M | -CN¥10.3M |
| Capital expenditure | CN¥81.0M | CN¥186M | CN¥270M | CN¥67.9M | CN¥144M |
| Total debt | CN¥3.61M | CN¥3.89M | CN¥1.30M | CN¥1.82M | CN¥1.96M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Allist Pharmaceuticals 688578.SS | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% |
| InnoCare Pharma 9969.HK | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% |
| Hansoh Pharma 3692.HK | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% |
| Betta Pharmaceuticals 300558.SZ | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% |
| Dizal Pharmaceutical 688192.SS | $4.02B | +9% | +720% | 69% | 7.8× | -11.0% |
| Yuhan 000100.KS | $4.11B | -10% | +8% | 6% | 40.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688578.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.5% | -1.7% | 4th lowest of 21 |
| 6-month return | -14.4% | +10.5% | 6th lowest of 21 |
| Distance from 52-week high | -42.9% | -27.9% | 5th lowest of 21 |
| Revenue growth (TTM) | +38.5% | +13.2% | 5th highest of 19 |
| Operating margin | 46.6% | 19.4% | 3rd highest of 19 |
| Forward P/E | 12.4× | 26.6× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 0.1% | 6.6% | 4th least demanding of 16 |
| Growth delivered (Del g) | +519.6% | +12.7% | highest of 16 |
| Hurdle (Req g minus delivered) | -519.5 pp | -2.5 pp | least demanding of 16 |
| ROIC minus cost of capital | +36.7 pp | +2.6 pp | 3rd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |